Anti-A beta drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Dongtak | - |
dc.contributor.author | Lee, Gyudo | - |
dc.contributor.author | Yoon, Dae Sung | - |
dc.date.accessioned | 2021-09-02T11:26:25Z | - |
dc.date.available | 2021-09-02T11:26:25Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-05-21 | - |
dc.identifier.issn | 0003-2654 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/75507 | - |
dc.description.abstract | Alzheimer's disease (AD) is the most common cause of neurodegenerative disorder in elderly people, and has become a social problem in aging societies globally. Amyloid-beta (A beta) aggregates (i.e., A beta fibrils and plaques) present in the brains of AD patients are hallmarks of AD. Although various promising anti-A beta drugs have been tested in pre-clinical and randomized controlled trials, the trial results have not yet been translated into clinical practice due to increasing time and cost of drug development. Recent investigations have addressed how the formation of A beta aggregates is influenced by the surface of gold nanoparticles (AuNPs) to obtain a detailed understanding of the in vivo process of amyloid formation. Particularly, AuNPs catalytically provide nucleation sites to accelerate the formation of A aggregates. Moreover, AuNPs have great potential as a sensing tool due to their optical property. Employing this dual function (i.e., catalytic and optical property), AuNP-based colorimetry is highlighted as a simple and innovative method for monitoring the efficacy of anti-A beta reagents. In this review, we briefly survey important developments and designs of anti-A beta drugs. The significance and perspectives of AuNP-based drug-screening in pharmacologic research are also discussed. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ROYAL SOC CHEMISTRY | - |
dc.subject | GOLD NANOPLASMONIC PARTICLES | - |
dc.subject | AMYLOID-BETA | - |
dc.subject | ANTIAGGREGATION REAGENTS | - |
dc.subject | COLORIMETRIC DETECTION | - |
dc.subject | SYNAPTIC PLASTICITY | - |
dc.subject | IN-VIVO | - |
dc.subject | PROTEIN | - |
dc.subject | AGGREGATION | - |
dc.subject | OLIGOMERS | - |
dc.subject | PEPTIDE | - |
dc.title | Anti-A beta drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Gyudo | - |
dc.contributor.affiliatedAuthor | Yoon, Dae Sung | - |
dc.identifier.doi | 10.1039/c7an02013a | - |
dc.identifier.scopusid | 2-s2.0-85047134831 | - |
dc.identifier.wosid | 000432265800003 | - |
dc.identifier.bibliographicCitation | ANALYST, v.143, no.10, pp.2204 - 2212 | - |
dc.relation.isPartOf | ANALYST | - |
dc.citation.title | ANALYST | - |
dc.citation.volume | 143 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 2204 | - |
dc.citation.endPage | 2212 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.subject.keywordPlus | GOLD NANOPLASMONIC PARTICLES | - |
dc.subject.keywordPlus | AMYLOID-BETA | - |
dc.subject.keywordPlus | ANTIAGGREGATION REAGENTS | - |
dc.subject.keywordPlus | COLORIMETRIC DETECTION | - |
dc.subject.keywordPlus | SYNAPTIC PLASTICITY | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | AGGREGATION | - |
dc.subject.keywordPlus | OLIGOMERS | - |
dc.subject.keywordPlus | PEPTIDE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.